ACP
GOSS icon

Acuta Capital Partners’s Gossamer Bio GOSS Stock Holding History

Acuta Capital Partners’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,556
Closed -$3.41M – 40
2022
Q3 		$3.41M Buy
3,556
+3,156
+789% +$3.13M 1.47% 20
2022
Q2 		$268K Buy
+400
New +$248K 0.15% 38
2022
Q1 		– Sell
-1,498
Closed -$1.35M – 43
2021
Q4 		$1.35M Sell
1,498
-1,190
-44% -$1.13M 0.57% 32
2021
Q3 		$2.7M Buy
+2,688
New +$1.98M 0.95% 28
2019
Q2 		– Sell
-750
Closed -$1.3M – 36
2019
Q1 		$1.3M Buy
+750
New +$1.25M 0.62% 28

Other funds holding GOSS

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acuta Capital Partners's GOSS Position: Q4 2022 in Review

Acuta Capital Partners sold out of Gossamer Bio (GOSS) in Q4 2022, closing a stake of 3,556 shares — an estimated $3.41M sold.

Acuta Capital Partners first reported a position in GOSS in Q1 2019 and held it in 5 quarters. The position peaked at $3.41M in Q3 2022. 118 funds tracked by Wall St. Rank hold GOSS as of Q4 2022.

  • Acuta Capital Partners reported no remaining Gossamer Bio position as of Q4 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 3,556 Gossamer Bio shares in Q4 2022, an estimated $3.41M.
  • Acuta Capital Partners first reported a position in Gossamer Bio in Q1 2019 and held it in 5 quarters.
  • Acuta Capital Partners's Gossamer Bio position peaked at $3.41M in Q3 2022.
  • 118 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.